过渡到高级心力衰竭:从识别到改善预后
Nikolaos-Iason Tepetes1, Christos Kourek2, Adamantia Papamichail3
1Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Journal of cardiovascular development and disease
|March 26, 2025
概括
晚期心力衰竭 (AHF) 是心力衰竭的最后阶段,需要全面管理. 本综述强调了当前和未来的策略,包括新型疗法和息治疗,以改善AHF患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 晚期心力衰竭 (AHF) 表示心力衰竭 (HF) 的末期阶段,尽管有指导方针导向的医疗疗疗法 (GDMT),但仍有持续的症状和功能下降.
- AHF是由严重的症状 (NYHA III-IV类),严重的心脏功能障碍和频繁的住院治疗定义的,这给管理带来了重大挑战.
研究的目的:
- 审查高级心力衰竭的临床定义,病理生理学和治疗策略.
- 探索AHF管理当前的局限性和未来的机遇.
主要方法:
- 对AHF的临床定义,病理生理学和治疗方法的文献综述.
- 对药理疗法,基于设备的干预,心脏移植和息治疗的分析.
主要成果:
- 关键的病理生理机制包括神经激素激活,心室重塑和全身炎症,导致心脏输出减少和器官功能障碍.
- 目前的治疗策略涉及多学科的方法,但限制,如访问差异和个性化需求仍然存在.
结论:
- 整合创新技术,人工智能,远程监控,个性化医学和息护理对于改善AHF的结果至关重要.
- 早期识别和及时干预对于改善晚期心力衰竭患者的生存和功能状况至关重要.
相关概念视频
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476
Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309


